{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:55:31Z","timestamp":1783468531251,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":2540,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1093\/annonc\/mds127","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T04:09:18Z","timestamp":1339733358000},"page":"3058-3063","source":"Crossref","is-referenced-by-count":57,"title":["Adjuvant trastuzumab cardiotoxicity in patients over 60\u00a0years of age with early breast cancer: a multicenter cohort analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Tarantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pulignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ceccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lestuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds127_bb0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00292-010-1348-4","article-title":"HER2 ASCO guidelines. The answer to everything?","volume":"31","author":"Burandt","year":"2010","journal-title":"Pathologe"},{"key":"10.1093\/annonc\/mds127_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mds127_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/mds127_bb0025","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1998.16.4.1340","article-title":"neu\/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group","volume":"16","author":"Andrulis","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds127_bb0030","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds127_bb0035","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds127_bb0040","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds127_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds127_bb0050","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds127_bb0055","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2005.02.3028","article-title":"Use and outcomes of adjuvant chemotherapy in older women with breast cancer","volume":"24","author":"Giordano","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds127_bb0060","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mds127_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mds127_bb0070","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr1523","article-title":"Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways","volume":"8","author":"Pugatsch","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mds127_bb0075","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","article-title":"Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes","volume":"41","author":"Timolati","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1093\/annonc\/mds127_bb0080","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","article-title":"Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study","volume":"23","author":"Doyle","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds127_bb0085","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds127_bb0090","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1002\/cncr.24621","article-title":"Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer","volume":"115","author":"Du","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds127_bb0095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/annonc\/mdn025","article-title":"Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations","volume":"19","author":"H\u00e9ry","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds127_bb0100","unstructured":"http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf"},{"key":"10.1093\/annonc\/mds127_bb0105","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1161\/01.CIR.98.21.2282","article-title":"Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991","volume":"98","author":"Senni","year":"1998","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mds127_bb0110","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1093\/annonc\/mds127_bb0115","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds127_bb0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/SLA.0b013e31822a7047","article-title":"Cancer trials versus the real world in the United States","volume":"254","author":"Al-Refaie","year":"2011","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds127_bb0125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin","year":"2009","journal-title":"J Card Fail"},{"key":"10.1093\/annonc\/mds127_bb0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","article-title":"Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study","volume":"117","author":"Wadhwa","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds127_bb0135","article-title":"Adjuvant chemotherapy for early breast cancer in Italy: what has changed today versus the early 2000's. A comparison between two observational national studies: NORA and NEMESI","volume":"21","author":"Mustacchi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds127_bb0140","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(07)70378-9","article-title":"Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology","volume":"8","author":"Wildiers","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds127_bb0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-011-1781-y","article-title":"Dual HER2-targeted approaches in HER2-positive breast cancer","volume":"131","author":"Ahn","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds127_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mds127_bb0155","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.06.142","article-title":"Can heart failure medications prevent trastuzumab-induced cardiotoxicity?","volume":"15","author":"Reynolds","year":"2009","journal-title":"J Cardiac Failure"},{"key":"10.1093\/annonc\/mds127_bb0160","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mds127_bb0165","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/12\/3058\/13786165\/mds127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:52:23Z","timestamp":1625169143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0923753419374691"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds127","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}